Algert Global LLC Novo Cure LTD Transaction History

Algert Global LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.83 - $24.05 $203,511 - $413,732	-17,203 Reduced 55.49%	13,800 $236,000
Q1 2024 May 14, 2024	BUY	$12.42 - $17.29 $385,057 - $536,041	31,003 New	31,003 $485,000
Q4 2022 Feb 13, 2023	SELL	$63.98 - $85.37 $85,477 - $114,054	-1,336 Reduced 19.92%	5,371 $394,000
Q3 2022 Nov 15, 2022	BUY	$67.99 - $89.57 $456,008 - $600,745	6,707 New	6,707 $510,000
Q1 2021 May 14, 2021	SELL	$124.11 - $190.17 $973,146 - $1.49 Million	-7,841 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$112.16 - $174.14 $1.24 Million - $1.93 Million	-11,099 Reduced 58.6%	7,841 $1.36 Million
Q3 2020 Nov 16, 2020	BUY	$58.05 - $111.31 $1.1 Million - $2.11 Million	18,940 New	18,940 $2.11 Million

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.